HUT73383A - Process for preparing cancer vaccines - Google Patents

Process for preparing cancer vaccines Download PDF

Info

Publication number
HUT73383A
HUT73383A HU9502720A HU9502720A HUT73383A HU T73383 A HUT73383 A HU T73383A HU 9502720 A HU9502720 A HU 9502720A HU 9502720 A HU9502720 A HU 9502720A HU T73383 A HUT73383 A HU T73383A
Authority
HU
Hungary
Prior art keywords
dna
cells
complex
transformed
cell
Prior art date
Application number
HU9502720A
Other languages
English (en)
Hungarian (hu)
Other versions
HU9502720D0 (en
Inventor
Max L Birnstiel
Michael Buschle
Matthew Cotten
Gerhard Maas
Christian Plank
Gotthold Schaffner
Walter Schmidt
Ernst Wagner
Kurt Zatloukal
Original Assignee
Boehringer Sohn Ingelheim
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT0055693A external-priority patent/AT399656B/de
Priority claimed from DE4326821A external-priority patent/DE4326821A1/de
Application filed by Boehringer Sohn Ingelheim, Genentech Inc filed Critical Boehringer Sohn Ingelheim
Publication of HU9502720D0 publication Critical patent/HU9502720D0/hu
Publication of HUT73383A publication Critical patent/HUT73383A/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/485Epidermal growth factor [EGF], i.e. urogastrone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/53Colony-stimulating factor [CSF]
    • C07K14/535Granulocyte CSF; Granulocyte-macrophage CSF
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/57IFN-gamma
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361Methods of inactivation or attenuation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/20011Rhabdoviridae
    • C12N2760/20111Lyssavirus, e.g. rabies virus
    • C12N2760/20122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HU9502720A 1993-03-19 1994-03-18 Process for preparing cancer vaccines HUT73383A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0055693A AT399656B (de) 1993-03-19 1993-03-19 Verfahren zur herstellung von krebsvakzinen
DE4326821A DE4326821A1 (de) 1993-08-10 1993-08-10 Verfahren zur Herstellung von Krebsvakzinen

Publications (2)

Publication Number Publication Date
HU9502720D0 HU9502720D0 (en) 1995-11-28
HUT73383A true HUT73383A (en) 1996-07-29

Family

ID=25593140

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9502720A HUT73383A (en) 1993-03-19 1994-03-18 Process for preparing cancer vaccines

Country Status (13)

Country Link
EP (1) EP0689604A1 (fi)
JP (1) JPH08507921A (fi)
KR (1) KR960701211A (fi)
CN (1) CN1119459A (fi)
AU (1) AU6427994A (fi)
CA (1) CA2158655A1 (fi)
CZ (1) CZ241795A3 (fi)
FI (1) FI954383A (fi)
HU (1) HUT73383A (fi)
NO (1) NO953684L (fi)
NZ (1) NZ263550A (fi)
PL (1) PL311036A1 (fi)
WO (1) WO1994021808A1 (fi)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0759695B1 (en) * 1994-05-13 2006-11-08 Thomas Jefferson University A method of inducing an immune response using vaccinia virus recombinants, expressing the gm-csf gene
US6093700A (en) 1995-05-11 2000-07-25 Thomas Jefferson University Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF
DE4426429A1 (de) * 1994-07-26 1996-02-01 Boehringer Ingelheim Int Verfahren zum Einführen von DNA in höhere eukaryotische Zellen
DE19510344C1 (de) * 1995-03-22 1996-11-07 Boehringer Ingelheim Int Verwendung einer Tumorvakzine
EP0835130A1 (en) * 1995-06-19 1998-04-15 University Of Medicine & Dentistry Of New Jersey Gene therapy of solid tumors with interferons alone or with other immuno-effector proteins
DE19608751B4 (de) * 1996-03-06 2006-05-18 Medigene Ag Verwendung eines Adeno-assoziierten Virus-Vektors zur Steigerung der Immunogenität von Zellen
US7001765B2 (en) 1996-03-06 2006-02-21 Medigene Ag Adeno-associated virus vector for boosting immunogenicity of cells
DE19608753C1 (de) * 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
DE19631357A1 (de) * 1996-08-02 1998-02-05 Deutsches Krebsforsch Vektor zur Aktivierung des Immunsystems gegen mit Papillomviren bzw. Sequenzen davon assoziierten Zellen
KR20010022863A (ko) * 1997-08-13 2001-03-26 피터 브이. 오`네일 유전자 벡터의 국소 적용에 의한 백신접종
ES2167939T3 (es) 1997-08-13 2002-05-16 Biontex Lab Gmbh Nuevas poliaminas, su preparacion y usos.
US7795020B2 (en) 1998-01-14 2010-09-14 Morphogenesis, Inc. Tumor cell vaccines
US7348015B2 (en) 1998-01-14 2008-03-25 Morphogenesis, Inc. Antigen modified cancer cell vaccines for cancer therapy
WO1999036433A2 (en) 1998-01-14 1999-07-22 Morphogenesis, Inc. Materials and methods for treating oncological disease
DK2295065T3 (da) 1998-02-20 2014-01-06 Univ Miami Modificeret varmechockprotein-antigenpeptidkompleks
CA2362578A1 (en) * 1999-02-09 2000-08-17 Kam Leong Tumor vaccines
BR0001029A (pt) * 2000-04-10 2001-11-20 Fk Biotecnologia Ltda Processo de transformação de células tumorais
AUPQ755300A0 (en) 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
DE10131148A1 (de) * 2001-06-28 2003-01-16 I P L Internat Pharmaceutics L Xenogene Oligo- oder/und Polyribonukleotide als Mittel zur Behandlung von malignen Tumoren
US7176022B2 (en) 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
US8475785B2 (en) 2008-03-03 2013-07-02 The University Of Miami Allogeneic cancer cell-based immunotherapy
JP2011515399A (ja) 2008-03-20 2011-05-19 ユニバーシティー オブ マイアミ 熱ショックタンパクgp96ワクチン接種及びそれを用いた方法
UA110119C2 (xx) * 2010-12-02 2015-11-25 Пептиди tomm34 та вакцини, що їх містять
EP3253876B1 (en) 2015-02-06 2020-11-04 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
EP3487999A4 (en) * 2016-07-25 2020-05-20 Ascend Biopharmaceuticals Ltd METHODS OF TREATING CANCER
WO2018071405A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
US11548930B2 (en) 2017-04-04 2023-01-10 Heat Biologics, Inc. Intratumoral vaccination
AU2018395010B2 (en) * 2017-12-29 2022-07-28 Genemedicine Co., Ltd. Cell sheet for gene delivery

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation

Also Published As

Publication number Publication date
NO953684D0 (no) 1995-09-18
HU9502720D0 (en) 1995-11-28
CN1119459A (zh) 1996-03-27
NZ263550A (en) 1996-12-20
WO1994021808A1 (de) 1994-09-29
FI954383A0 (fi) 1995-09-18
NO953684L (no) 1995-09-18
CA2158655A1 (en) 1994-09-29
EP0689604A1 (de) 1996-01-03
AU6427994A (en) 1994-10-11
JPH08507921A (ja) 1996-08-27
KR960701211A (ko) 1996-02-24
CZ241795A3 (en) 1996-04-17
PL311036A1 (en) 1996-01-22
FI954383A (fi) 1995-09-18

Similar Documents

Publication Publication Date Title
HUT73383A (en) Process for preparing cancer vaccines
Brossart et al. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL.
AU671084B2 (en) Composition for inserting nucleic acid complexes into higher eucaryotic cells
EP1015035B1 (en) Vaccination by topical application of genetic vectors
KR102100092B1 (ko) 이종 종양-관련 항원들을 발현하는 아데노바이러스
EP0551401B2 (en) Methods and compositions for genetic therapy and potentiation of anti-tumor immunity
JP2001508304A (ja) 細胞内及び細胞間輸送のための融合タンパク質、並びにその使用
US6706693B1 (en) Vaccination by topical application of genetic vectors
Liu et al. Systemic genetic transfer of p21WAF− 1 and GM-CSF utilizing of a novel oligopeptide-based EGF receptor targeting polyplex
Datta et al. Lysine: Is it worth more?
WO2004035769A1 (en) Improved immunotherapy
CN115806626B (zh) 一种基于csf1的嵌合抗原受体免疫细胞制备及其应用
EP1240317B1 (en) Nucleic acid vaccination
JP4423507B2 (ja) 癌遺伝子治療薬
US6689605B1 (en) Controlling immune response to specific antigens
US7064111B1 (en) Use of soluble costimulatory factor for tumor immuno-gene therapy
Eslahi et al. Fusogenic activity of vesicular stomatitis virus glycoprotein plasmid in tumors as an enhancer of IL-12 gene therapy
WO1998052615A1 (en) Controlling immune response to specific antigens
KR100241685B1 (ko) 핵산 복합체를 고등 진핵세포내로 도입시키기 위한 조성물
CA2365026A1 (en) Virus vector
WO1999036440A2 (en) Expression of fusion proteins
Sherr et al. SESSION I: TUMOUR BIOLOGY AND ANTI-TUMOUR IMMUNITY
Hrušková Construction of various types of vaccines based on the structural proteins of mouse polyomavirus and analysis of immune response after their administration to mice
JP2003511394A (ja) 腫瘍免疫−遺伝子治療のための可溶性補助刺激因子の使用
DE4326821A1 (de) Verfahren zur Herstellung von Krebsvakzinen

Legal Events

Date Code Title Description
DFD9 Temporary protection cancelled due to non-payment of fee